Abdul Mannan: When Blood Clots Show Up in Unexpected Places
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“When Blood Clots Show Up in Unexpected Places
Most doctors think DVT and PE when they hear ‘blood clot.’
But as a Thrombosis Lead, I spend a lot of time managing clots that don’t follow the textbook. The ones that form in the brain. In the liver veins. In the portal system.
These are the cases that keep haematologists busy — and they demand a completely different mindset.
Let’s talk about two locations that matter:
Splanchnic Vein Thrombosis (Abdomen)
When I see Budd-Chiari syndrome, my first question isn’t “why did this clot form?”
It’s “which myeloproliferative neoplasm am I going to find?”
Because MPNs account for nearly half of all cases. That’s 49%. And here’s the thing — sometimes the clot appears before any other sign of the blood cancer. The thrombosis IS the presentation.
Portal vein thrombosis tells a different story. Liver cirrhosis dominates here. Sluggish flow. Damaged vessels. The perfect storm for clot formation.
In both scenarios, anticoagulation remains the treatment backbone — even when it feels counterintuitive. Without it, clot extension leads to intestinal infarction. And that’s a disaster.
Cerebral Vein Thrombosis (Brain)
Three times more common in women. Pregnancy. Oral contraceptives. The hormonal connection is undeniable.
90% present with severe headache. Not a mild one — the kind that brings patients to A&E thinking the worst.
Now here’s what surprises many colleagues:
We anticoagulate even when there’s hemorrhage on imaging.
Yes, you read that right. About 40% of CVT patients have hemorrhagic transformation at diagnosis. We still anticoagulate. The evidence supports it. The clot needs treatment, and the bleeding is usually a consequence of venous congestion, not arterial rupture.
Two principles I live by:
1. Always hunt for the underlying cause. Atypical clots are often the tip of the iceberg. MPNs. Paroxysmal nocturnal haemoglobinuria. Antiphospholipid syndrome. Behçet’s disease. Don’t stop until you’ve looked.
2. Think long-term. These aren’t your standard three-month anticoagulation cases. When we find a persistent prothrombotic condition, indefinite treatment becomes the conversation.
Atypical site thrombosis is rare. But when it happens, getting it right changes lives.
Have you encountered challenging atypical thrombosis cases? What was the underlying diagnosis?”
Find more posts featuring Abdul Mannan on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?